guest ::
| Home > Publications Database > Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease. > print |
| Home > Publications Database > Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease. > print |
| 001 | 136957 | ||
| 005 | 20240614154057.0 | ||
| 024 | 7 | _ | |a 10.1016/j.bcp.2012.12.007 |2 doi |
| 024 | 7 | _ | |a pmid:23291240 |2 pmid |
| 024 | 7 | _ | |a 0006-2952 |2 ISSN |
| 024 | 7 | _ | |a 1873-2968 |2 ISSN |
| 024 | 7 | _ | |a altmetric:6726000 |2 altmetric |
| 037 | _ | _ | |a DZNE-2020-03279 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Popp, Julius |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2013 |b Elsevier Science |
| 264 | _ | 1 | |3 print |2 Crossref |b Elsevier BV |c 2013-07-01 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1718372417_616 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The disturbances of the cholesterol synthesis and metabolism described in Alzheimer's disease (AD) may be both a consequence of the neurodegenerative process and a contributor to the pathogenesis. These putative relationships and their underlying mechanisms are not well understood. The aim of this study was to evaluate the relationship between the cerebral and extracerebral cholesterol synthesis and metabolism, and the AD pathology as reflected by CSF markers in humans. We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of cholesterol, the cholesterol precursors lanosterol, lathosterol and desmosterol, and the cholesterol elimination products 24S-hydroxycholesterol and 27-hydroxycholesterol, and the CSF markers for AD pathology Aβ1-42 and p-tau181 in 86 subjects with normal cognition and in 107 AD patients. CSF desmosterol, cholesterol and 24S-hydroxycholesterol in the AD group, and CSF 24S-hydroxycholesterol in the control group correlated with the p-tau181 levels. Neither CSF nor plasma concentrations of the included compounds correlated with the CSF Aβ1-42 levels. In multivariate regression tests including age, gender, albumin ratio, number of the APOEε4 alleles, and diagnosis, p-tau181 levels independently predicted the CSF desmosterol, cholesterol and 24S-hydroxycholesterol concentrations. The associations remained significant for CSF cholesterol and 24S-hydroxycholesterol when analyses were separately performed in the AD group. The results suggest that alterations of CNS cholesterol de novo genesis and metabolism are related to neurodegeneration and in particular to the cerebral accumulation of phosphorylated tau. |
| 536 | _ | _ | |a 344 - Clinical and Health Care Research (POF3-344) |0 G:(DE-HGF)POF3-344 |c POF3-344 |f POF III |x 0 |
| 542 | _ | _ | |i 2013-07-01 |2 Crossref |u https://www.elsevier.com/tdm/userlicense/1.0/ |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a Amyloid |2 NLM Chemicals |
| 650 | _ | 7 | |a Biomarkers |2 NLM Chemicals |
| 650 | _ | 7 | |a tau Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a Cholesterol |0 97C5T2UQ7J |2 NLM Chemicals |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a Alzheimer Disease: blood |2 MeSH |
| 650 | _ | 2 | |a Alzheimer Disease: cerebrospinal fluid |2 MeSH |
| 650 | _ | 2 | |a Alzheimer Disease: metabolism |2 MeSH |
| 650 | _ | 2 | |a Amyloid: metabolism |2 MeSH |
| 650 | _ | 2 | |a Biomarkers: blood |2 MeSH |
| 650 | _ | 2 | |a Biomarkers: cerebrospinal fluid |2 MeSH |
| 650 | _ | 2 | |a Brain: metabolism |2 MeSH |
| 650 | _ | 2 | |a Case-Control Studies |2 MeSH |
| 650 | _ | 2 | |a Cholesterol: metabolism |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a tau Proteins: metabolism |2 MeSH |
| 700 | 1 | _ | |a Meichsner, Sabrina |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Kölsch, Heike |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Lewczuk, Piotr |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Maier, Wolfgang |0 P:(DE-2719)2000015 |b 4 |u dzne |
| 700 | 1 | _ | |a Kornhuber, Johannes |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Jessen, Frank |0 P:(DE-2719)2000032 |b 6 |u dzne |
| 700 | 1 | _ | |a Lütjohann, Dieter |0 P:(DE-HGF)0 |b 7 |
| 773 | 1 | 8 | |a 10.1016/j.bcp.2012.12.007 |b : Elsevier BV, 2013-07-01 |n 1 |p 37-42 |3 journal-article |2 Crossref |t Biochemical Pharmacology |v 86 |y 2013 |x 0006-2952 |
| 773 | _ | _ | |a 10.1016/j.bcp.2012.12.007 |g Vol. 86, no. 1, p. 37 - 42 |0 PERI:(DE-600)1496199-4 |n 1 |q 86:1<37 - 42 |p 37-42 |t Biochemical pharmacology |v 86 |y 2013 |x 0006-2952 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/136957/files/DZNE-2020-03279_Restricted.pdf |
| 856 | 4 | _ | |u https://pub.dzne.de/record/136957/files/DZNE-2020-03279_Restricted.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |p VDB |o oai:pub.dzne.de:136957 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 4 |6 P:(DE-2719)2000015 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 6 |6 P:(DE-2719)2000032 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-344 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2013 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BIOCHEM PHARMACOL : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-2719)999999 |k Pre 2020 |l DZNE before 2020 |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)7000001 |k U Clinical Researchers - Bonn |l U Clinical Researchers - Bonn |x 1 |
| 920 | 1 | _ | |0 I:(DE-2719)1011102 |k AG Jessen |l Clinical Alzheimer’s Disease Research |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)999999 |
| 980 | _ | _ | |a I:(DE-2719)7000001 |
| 980 | _ | _ | |a I:(DE-2719)1011102 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|